Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer
June 15, 2023 06:30 ET
|
Cerevel Therapeutics
Mr. Burgess will be responsible for leading Cerevel’s business development and quality teams Mr. Burgess to join Cerevel effective June 20, 2023 CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) --...
Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial Officer
May 10, 2023 06:30 ET
|
Cerevel Therapeutics
Susan Altschuller, Ph.D. brings financial management, investor relations, and business planning experience from leading pharmaceutical and biotechnology companies to Cerevel Dr. Altschuller to...
Cerevel Therapeutics Appoints Ron Renaud as President and Chief Executive Officer and Reports First Quarter 2023 Financial Results
May 03, 2023 06:30 ET
|
Cerevel Therapeutics
Ron Renaud to succeed Tony Coles, M.D. as CEO, effective June 12, 2023; Dr. Coles will continue as chairperson of the board Mr. Renaud brings more than 25 years of biotechnology leadership to...
Cerevel Therapeutics to Present at the BofA Securities 2023 Health Care Conference
April 26, 2023 06:30 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced...
Cerevel Therapeutics to Report First Quarter 2023 Financial Results and Business Updates on Wednesday, May 3, 2023
April 11, 2023 06:30 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced...
Cerevel Therapeutics to Present at the Stifel 2023 CNS Days
March 21, 2023 06:30 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today...
Cerevel Therapeutics to Present at the 43rd Annual Cowen Health Care Conference
March 02, 2023 06:30 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today...
Cerevel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
February 22, 2023 06:30 ET
|
Cerevel Therapeutics
Emraclidine Phase 1 healthy elderly volunteer trial enrollment underway to support development in Alzheimer’s disease psychosis Emraclidine Phase 2 schizophrenia data readout remains on track for 1H...
Cerevel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates on Wednesday, February 22, 2023
February 01, 2023 06:30 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced...
Cerevel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference and Provide Pipeline Update
January 09, 2023 06:30 ET
|
Cerevel Therapeutics
Initiated Phase 1 healthy volunteer trial to support development of emraclidine in Alzheimer’s disease psychosis in Q4 2022; second potential indication as a once-daily treatment Phase 2...